| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer
|
Filho, Otto Metzger
|
|
|
185 |
1 |
p. 135-144
|
artikel
|
| 2 |
Association between body mass index and localization of breast cancer: results from a nationwide inpatient database in Japan
|
Konishi, Takaaki
|
|
|
185 |
1 |
p. 175-182
|
artikel
|
| 3 |
Body mass index (BMI) and benefit from adjuvant chemotherapy in breast cancer: is it enough?
|
Palleschi, Michela
|
|
|
185 |
1 |
p. 255-256
|
artikel
|
| 4 |
Efficacy of anti-HER2 therapy in metastatic breast cancer by discordance of HER2 expression between primary and metastatic breast cancer
|
Van Raemdonck, Elisa
|
|
|
185 |
1 |
p. 183-194
|
artikel
|
| 5 |
Factors associated with late-stage diagnosis of breast cancer among women in Addis Ababa, Ethiopia
|
Gebremariam, Alem
|
|
|
185 |
1 |
p. 117-124
|
artikel
|
| 6 |
Family history of breast cancer in men with non-BRCA male breast cancer: implications for cancer risk counseling
|
Calip, Gregory S.
|
|
|
185 |
1 |
p. 195-204
|
artikel
|
| 7 |
FDG-PET/CT in high-risk primary breast cancer—a prospective study of stage migration and clinical impact
|
Vogsen, Marianne
|
|
|
185 |
1 |
p. 145-153
|
artikel
|
| 8 |
Impact of adjuvant chemotherapy or tamoxifen-alone on the ovarian reserve of young women with breast cancer
|
Goldfarb, Shari B.
|
|
|
185 |
1 |
p. 165-173
|
artikel
|
| 9 |
Impact of patients’ refusal to undergo adjuvant treatment measures on survival
|
Männle, H.
|
|
|
185 |
1 |
p. 239-246
|
artikel
|
| 10 |
Impalpable breast lesion localisation, a logistical challenge: results of the UK iBRA-NET national practice questionnaire
|
Somasundaram, Santosh K.
|
|
|
185 |
1 |
p. 13-20
|
artikel
|
| 11 |
Incidence and survival of inflammatory breast cancer between 1973 and 2015 in the SEER database
|
Abraham, Hannah Grace
|
|
|
185 |
1 |
p. 229-238
|
artikel
|
| 12 |
Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer
|
Mohamadzade, Zahra
|
|
|
185 |
1 |
p. 95-106
|
artikel
|
| 13 |
Long-term survival outcomes of repeat lumpectomy for ipsilateral breast tumor recurrence: a propensity score-matched analysis
|
Baek, Soo Yeon
|
|
|
185 |
1 |
p. 155-164
|
artikel
|
| 14 |
Metformin and an insulin/IGF-1 receptor inhibitor are synergistic in blocking growth of triple-negative breast cancer
|
Xue, Lei
|
|
|
185 |
1 |
p. 73-84
|
artikel
|
| 15 |
Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center
|
Losk, Katya
|
|
|
185 |
1 |
p. 215-227
|
artikel
|
| 16 |
Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients
|
Yusufov, Miryam
|
|
|
185 |
1 |
p. 53-62
|
artikel
|
| 17 |
Quantitative proteomics reveals stage-specific protein regulation of triple negative breast cancer
|
Lin, Yuxiang
|
|
|
185 |
1 |
p. 39-52
|
artikel
|
| 18 |
Risk of heart failure after systemic treatment for early breast cancer: results of a cohort study
|
Jacobse, Judy N.
|
|
|
185 |
1 |
p. 205-214
|
artikel
|
| 19 |
Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment
|
Deng, Jiehui
|
|
|
185 |
1 |
p. 85-94
|
artikel
|
| 20 |
Telerehabilitation for patients with breast cancer through the COVID-19 pandemic
|
de Rezende, Laura Ferreira
|
|
|
185 |
1 |
p. 257-259
|
artikel
|
| 21 |
The efficacy and safety of pertuzumab plus trastuzumab and docetaxel as a first-line therapy in Japanese patients with inoperable or recurrent HER2-positive breast cancer: the COMACHI study
|
Takahashi, Masato
|
|
|
185 |
1 |
p. 125-134
|
artikel
|
| 22 |
The prognostic and predictive role of the neutrophil-to-lymphocyte ratio and the monocyte-to-lymphocyte ratio in early breast cancer, especially in the HER2+ subtype
|
Tiainen, Satu
|
|
|
185 |
1 |
p. 63-72
|
artikel
|
| 23 |
Tolerability and toxicity of trastuzumab or trastuzumab + lapatinib in older patients: a sub-analysis of the ALTTO trial (BIG 2-06; NCCTG (Alliance) N063D)
|
Pondé, Noam
|
|
|
185 |
1 |
p. 107-116
|
artikel
|
| 24 |
Tumor necrosis by pretreatment breast MRI: association with neoadjuvant systemic therapy (NAST) response in triple-negative breast cancer (TNBC)
|
Abdelhafez, Abeer H.
|
|
|
185 |
1 |
p. 1-12
|
artikel
|
| 25 |
Vitiligo-like lesions in patients with advanced breast cancer treated with cycline-dependent kinases 4 and 6 inhibitors
|
Sollena, Pietro
|
|
|
185 |
1 |
p. 247-253
|
artikel
|
| 26 |
Width of margins in phyllodes tumors of the breast: the controversy drags on?—a systematic review and meta-analysis
|
Toussaint, Arnaud
|
|
|
185 |
1 |
p. 21-37
|
artikel
|
Tijdschrift beschrijving